News

The Nextstep program has officially opened its second round of applications, offering 10 fully funded PhD fellowships scheduled to begin in Autumn 2026. These positions represent the first tranche of a total of 18 spots that will be made available between February and March 2026. Program Details Supported by the MSCA COFUND actions of Horizon Europe, the project aims to cultivate a new generation of researchers within a world-class international setting. Research Fields: Physics, materials science, chemistry, biochemistry, and engineering Technological Focus: Utilization of advanced neutron, X-ray, and electron microscopy techniques to address challenges in sustainability and industrial competitiveness Host Institutions: ESRF, ILL, Forschungszentrum Jülich (FZJ), and Area Science Park. In addition to working at one of these leading European research institutions, PhD candidates will benefit from enrollment in a doctoral program at a partner university and a secondment period of at least two months with academic or industrial partners. Regarding the PhD program to be developed at Area Science Park, the focus will be on the advanced study of functional materials using high-resolution Transmission Electron Microscopy (TEM) techniques, including in-situ and operando methodologies. The objective is to analyze the nanostructure of materials down to sub-Angstrom resolution, as well as to study their evolution under realistic operating conditions by applying various stimuli such as temperature, electric fields, and reactive environments (liquids or gases). The selected candidate will be enrolled in the PhD program in Nanotechnology at the University of Trieste and will conduct their research activity full-time at the Electron Microscopy Laboratory (LAME) of Area Science Park in Trieste. How to Apply: Submit your application at https://nextstep-programme.eu/job-offers/. Deadline: March 31, 2026.

The INGenIO project submitted by Area Science Park under the competitive call of the National Programme for Research, Innovation and Competitiveness 2021–2027 of the Ministry of University and Research (MUR) has secured funding of over €21 million. The funding will support the development of an integrated, interoperable and distributed infrastructure for the diagnosis, molecular understanding and identification of personalised therapies for rare diseases—conditions that affect around 30 million people in Europe alone. The project ranked fifth in the merit list, with a score of 96/100. INGenIO (Next-Generation Digital Infrastructure for the Study of Rare Diseases: Target Identification Guided by Multi-Omics & A.I. for Precision Drug Discovery & Delivery) aims to analyse clinical data from patients with rare diseases using Artificial Intelligence techniques designed to enable early diagnosis and identify potential drugs. On the experimental side, the project integrates Area Science Park’s multi-omics and digital technologies with magnetic resonance methods, electron microscopy and advanced preparative techniques available at partner laboratories. By bringing together specialised expertise and equipment across the national territory, the project will cover the entire value chain—from disease study to computational modelling and the synthesis of new drug candidates. INGenIO, coordinated by Area Science Park, builds on the organisation’s experience in designing and implementing research infrastructures focused on life sciences, including the Pathogen Readiness Platform for the CERIC-ERIC Upgrade (PRP@CERIC) for the study of pathogens and the ORFEO data centre. The project relies on a strong partnership including the University of Salerno, the University of Salento, the University of Florence, the CNR – Institute of Materials (IOM), the University of Naples “Federico II”, which brings collaboration with TIGEM, the CERM Magnetic Resonance Centre in Florence, and ENEA in Casaccia. This is complemented by a network of companies—particularly SMEs in Southern Italy—that have already expressed interest in collaborating on the project. The project structure integrates the expertise needed to cover the entire translational research cycle and its links with the industrial system. A distinctive feature of INGenIO, which expands the offering of the European infrastructure CERIC, is the functional integration of specialised laboratories distributed across the country and belonging to two other European research infrastructures, INSTRUCT and METROFOOD. In this way, a portfolio of instruments and expertise unique in Europe is oriented towards achieving a shared scientific objective—ambitious and with a high impact on health and society. “INGenIO’s 100% funding and its high ranking in the national list represent an important achievement for the organisation, which in recent years has focused its activities and investments on developing research infrastructures open to both the scientific community and industry,” said Area Science Park President Prof. Caterina Petrillo. “In particular, the project is an important booster to strengthen and relaunch the development strategies of the Area Sud site in Salerno, where, together with the university, we work on multi-omics characterisation in close synergy with our laboratories in Trieste”.

The Board of Directors of Area Science Park appointed Giorgio Graditi as the new Director General of the national research organization at its board meeting on 17 December 2025. Following a public selection procedure and a thorough evaluation process, the Board, following a proposal by Area Science Park’s president Professor Caterina Petrillo, approved Graditi’s appointment as Director General. Currently Director General of ENEA and a leading figure in the field of research and technological development in the energy sector, Graditi will take office on 1 March 2026 with a five-year mandate. Graditi previously served as Director of ENEA’s Department of Energy Technologies and Renewable Sources and contributed to the development of national and European strategies, projects, and initiatives in the fields of energy, digital and ecological transition, and sustainable development. His current positions include the Presidency of Medener, the association of national agencies for energy efficiency and renewable energy sources in the Mediterranean recognized by the European Commission; the Presidency of SIET (Società Informazioni Esperienze Termoidrauliche S.p.A.), which operates in the nuclear sector; membership of the Board of Directors of the University of Cassino and Southern Lazio; membership of the Board of Directors of the NEST Foundation (Network for Energy Sustainable Transition); membership of the Scientific Board of the Rome Technopole Foundation; and membership – serving as coordinator – of the Scientific Board of the National Energy Technology Cluster.    

A groundbreaking research project, supported by the European Research Infrastructures Consortium CERIC-ERIC, has shed new light on one of the most unusual and little-known chapters of human history: how human skin used to be tattooed – and then preserved – centuries ago. The study, recently published in the journal Heritage Science, combines history, chemistry, anthropology, and conservation science to better understand and protect rare tattooed skin fragments, many over a century old, held in the historic “Luigi Cattaneo” Anatomical Wax Collection at the University of Bologna. The research, which involved a multidisciplinary team from CERIC-ERIC, the Italian Space Agency (ASI), Elettra Sincrotrone Trieste, the University of Bologna, the University of Rome “Tor Vergata” and the Abdus Salam International Centre for Theoretical Physics (ICTP), offers a unique window into past tattooing practices, cultural traditions, and the ways museums once collected and studied the human body. Tattooing is an ancient human practice found across cultures and eras, from the 5,000-year-old tattooed “Ötzi” mummy discovered in the Alps to medieval Christian pilgrims who marked their bodies as signs of faith. But alongside this rich history lies a darker legacy: the collection of tattooed human skin by early scientists, criminologists, and museums, particularly during the 19th century. At that time, tattoos were mistakenly viewed as signs of criminality or “primitive” behavior, ideas promoted by influential but now-discredited figures such as Italian criminologist Cesare Lombroso. This led to the preservation of tattooed skin in museums and research institutions across Europe. The tattooed fragments studied in this research primarily represent the Loreto tattooing tradition – a devotional practice geographically confined to central Italy and intimately connected to pilgrimages to the Holy House of Loreto, a major Catholic sanctuary in the Marche region. “These tattoos – explains Monia Vadrucci, researcher at ASI and first author of the study – reveal intimate stories of individuals who lived in central Italy between the late 18th and early 20th centuries. Religious subjects – Madonnas of Loreto, monstrances, Sacred Hearts – testify to pilgrimages made to the Sanctuary of the Holy House, a journey that for peasants and people of humble origins represented a difficult undertaking, often accomplished on foot through the countryside. The date “1881” inscribed next to a Madonna, for example, immortalizes not only the year of the pilgrimage but probably a crucial moment in that person’s life: a grace received, a promise kept, or an act of thanksgiving”. The tattoo, performed with rudimentary three-pointed iron tools, became a permanent ex-voto, a physical bond with the divine imprinted on the skin – primarily on the wrists – recalling the stigmata of Christ and Saint Francis. Alongside sacred symbols, profane and erotic tattoos also emerge, evidence of a popular culture that mixed devotion and carnality without apparent contradiction. “The differences observed among the specimens, which suggest individuals of varying ages,” adds Stefano Ratti, Professor of Human Anatomy at the University of Bologna and scientific expert of the “Luigi Cattaneo” Anatomical Wax Collection, “indicate that these people carried their tattoos throughout their lives-indelible marks of moments that defined their spiritual and social identity in an era when the body itself became a book of memory”. The tattooed skin pieces were rediscovered only recently in museum storage. With little documentation surviving about their origins, researchers saw an opportunity to study them with modern, non-invasive investigation methods that would protect the extremely fragile specimens while revealing their secrets: “Through advanced spectroscopic analyses conducted at Elettra Sincrotrone Trieste – explains Chiaramaria Stani, former CERIC researcher who is now beamline scientist at Elettra – we identified traditional pigments such as plant-based carbon black for black tattoos, natural earth pigments for browns, and a mixture of cinnabar and minium for reds. But we also discovered traces of zinc and lime compounds, possibly suggesting the museum conservation methods of the time. This multidisciplinary approach allows us to document a nearly extinct cultural practice and develop specific conservation protocols for these unique materials”. This research offers valuable insights into the moral, social, and religious dimensions of tattooing in 19th century Italy, contributing to the understanding of tattooing evolution from a devotional and identity-based practice to a contemporary art form. It also establishes a framework for museums worldwide that care for similar materials – many of which also lack documentation or face conservation challenges. Future investigations aim to expand the scientific techniques used and explore archival sources to better understand who these individuals were and how their tattooed skin came to be preserved. The research team also emphasizes the importance of addressing the ethical dimensions of studying and exhibiting human remains, recognizing them as sensitive materials that require respectful treatment while acknowledging their cultural and scientific value.

The results of an important study published in the scientific journal Cell Reports describe the development of a new model capable of reconstructing key physiological features of the human liver, allowing the pathological processes that drive liver degeneration to be closely observed in the laboratory. The study, supported by AIRC Foundation for Cancer Research, has been coordinated by Giovanni Sorrentino, Group Leader, Advanced Disease Models at ICGEB, and Associate Professor of Histology at the University of Trieste, and comprises a multidisciplinary team including biotechnologists, physicists, and clinicians, to integrate cellular biology, genomics, tissue engineering, and direct clinical observations to develop the unique research platform. “The new system makes it possible to recreate the pathological activation of liver stem cells in the laboratory,” says Sorrentino, an expert in in vitro tissue engineering based on stem cell technologies and three-dimensional organoids. “In the early stages of chronic liver disease, this process has regenerative purposes. However, when it persists, it becomes one of the main factors in inflammation, tissue scarring, and progression toward advanced liver disease, including liver cancer.” For the first time, the model developed by researchers allows the observation of the pathological processes that drive liver tissue degeneration in chronic diseases and tumour progression in a three-dimensional environment that faithfully reproduces the complexity of the human liver, preserving the interactions between different cell populations. The researchers have discovered that reactive stem cell populations are critically dependent on their ability to synthesise cholesterol. Drugs widely used in clinical practice to lower cholesterol (such as statins) can halt the process of blocking abnormal stem cell activation, reducing inflammation and significantly slowing disease progression in chronic liver diseases. “In recent years,” comments Sorrentino, “clinical data from large patient populations have shown that people taking statins for the treatment of cardiovascular disease also show a slowdown in the progression of chronic liver diseases and a reduced risk of developing liver tumours such as cholangiocarcinoma, which results from prolonged abnormal activation of stem cells.” This study could reveal the molecular mechanisms underlying this connection, explaining why statins exert a protective effect. Beatrice Anfuso, Suresh Velnati, and Davide Selvestrel, the study’s lead authors, confirm that these results represent a decisive step forward. Thanks to the diverse expertise of team members, it has been possible to develop a platform that clarifies how the disease manifests itself and also reveals its initial vulnerabilities. The fact that one of these vulnerabilities can be treated with already approved drugs makes the discovery promising for early therapeutic intervention and disease prevention.

On the occasion of the year-end holiday season, we inform you that the organisation will be closed on the following days: 29, 30 and 31 December 2025 2 and 5 January 2026   Due to reduced attendance across the Area Science Park campuses, catering and bar services will operate with the following changes: Canteen and bar closures: 25–28 December 2025 2 and 5 January 2026 Pizzeria closure: 22 December 2025 to 6 January 2026 Reduced catering and bar services: On 24, 29, 30 and 31 December 2025, only one self-service line will be available. From 22 to 31 December 2025, the bar will operate reduced hours: 8:00 a.m. to 3:00 p.m. Our best wishes for a happy holiday season and for a 2026 full of satisfaction and success!

The ICGEB and the Developing Countries Vaccine Manufacturers Network (DCVMN) have launched a Technology Transfer Training Programme with the aim of equipping low- and middle-income countries with the necessary knowledge and skills to accelerate the production of vaccines that can protect against emerging infectious diseases. The training course includes the participation of ten delegates from nine DCVMN member companies from countries such as Argentina, Ghana, India, Nicaragua, Thailand, and Vietnam. The training programme includes a five-week online component and a one-week laboratory training session. The first part covers the theoretical foundations of technology transfer, including Intellectual Property (IP) and licensing, GMP (Good Manufacturing Practice) and regulatory considerations, different vaccine process platforms, and a roadmap for successful execution. The second phase takes place at the ICGEB’s Biotechnology Development Unit in Trieste and offers a practical and immersive experience in a GMP-like environment, allowing participants to put the learned concepts into practice. At the conclusion of the course, participants will return to their organizations with the necessary know-how to share the knowledge, amplify the impact of the training, and translate the learnings into concrete actions for vaccine development and production in their countries.

Support cities and regions across the Mediterranean in their fight against climate change by promoting swift, joint action to mitigate further adverse environmental, social, and economic impacts. This is the core objective of the INFIRE project — INnovative FInancing solutions for climate planning of REsilient and carbon neutral living areas — which brings together 10 expert partners with highly complementary skills. They are working together to build a long-term support framework to strengthen the capacity of public authorities in the participating regions to develop, implement, and monitor holistic policy solutions and tools for climate adaptation and carbon neutrality. To this end, the Train-the-Trainer (TtT) workshop was held at Area Science Park, bringing together technical partners from seven Mediterranean countries for two days of learning, peer exchange, and hands-on activities. The goal was to consolidate tools and methodologies that will be transferred to pilot municipalities in the next project phase, set to launch in the final months of 2025. Key topics aimed at strengthening public authorities’ competencies were addressed: from understanding the main public and private funding schemes — including innovative models such as public-private partnerships (PPPs) and citizen-led initiatives — to the criteria for selecting the most suitable financial instruments based on the specific features of different interventions. Operational aspects related to green bonds and climate bonds were also explored in depth, including eligibility criteria, issuance procedures, investor requirements, and reporting obligations, with specific attention to the needs of smaller municipalities. Finally, substantial focus was placed on building strong and efficient data management systems, which are essential for monitoring and evaluating local climate adaptation actions. Participants worked on indicators, data quality, and interoperability, developing critical skills to ensure decisions are based on reliable evidence. For more information about the INFIRE Project, click HERE.

The first NACHIP Open Call is officially open to fund innovative solutions along the hydrogen value chain, with an application deadline of 3 February 2026. NACHIP (North Adriatic Clean Hydrogen Investment Platform) is a platform co-funded by the European Union through the I3 instrument, aimed at accelerating clean hydrogen-related technologies in the fields of production, mobility, and urban areas. The NACHIP call is dedicated to supporting mature technological solutions in the hydrogen sector, with particular focus on innovative products, services, or processes applicable across the hydrogen value chain. Selected projects must contribute to the development, integration, or demonstration of already validated technologies (high TRL), in line with the needs of the NACHIP pilot projects in clean hydrogen production, mobility, and urban applications. The call offers up to €60,000 to highly innovative SMEs or consortia of small enterprises, funding projects with a high level of technological maturity (Technology Readiness Level > 7). The total budget available for this first open call is €540,000, covering 100% of eligible costs through a cascade funding mechanism. Eligible applicants include SMEs active in hydrogen technologies, components, digital solutions, and other relevant fields, registered in eligible EU regions (including Friuli Venezia Giulia, Veneto, Lazio, Umbria, Slovenia, and Croatia). Proposals will be evaluated based on their strategic impact and their ability to address the technical needs of the NACHIP project and the five pilot projects foreseen under the programme. To learn more: Launch of the NACHIP Open Call for SMEs – Funding Innovative Hydrogen Solutions – NACHIP

Creating a meeting place between different disciplines, where students and researchers can acquire new tools and skills to address scientific questions at the interface between physics and biology. This was the aim of the first biophysics school in Guatemala, that was held at the University of the Valley from November 26th to December 5th, promoted by ICTP – International Centre for Theoretical Physics with the participation of Area Science Park. Francesca Cuturello, a researcher at the Data Engineering Laboratory (LADE) at Area Science Park, took part in the initiative with the course “Machine Learning for Structural Biology.” In her presentation, Cuturello illustrated how statistical artificial intelligence models can be used to understand the structure and function of biomolecules. Edith Natalia Villegas Garcia, a PhD student in the Area, was also among the organizers and teaching assistant for the Machine Learning course. The school represents an important step toward building an international biophysics network, with the aim of promoting biophysics research and creating lasting links between Guatemalan universities and the international scientific community.

An international group of researchers from the MRC Laboratory of Molecular Biology and the Wellcome Sanger Institute in Cambridge, led by Gianluca Petris — now Principal Investigator of the Genome Engineering & Biotechnology Unit at the Fondazione Italiana Fegato and lecturer in the Department of Medicine at the University of Udine – has achieved an unprecedented result: transferring, modifying, and replacing entire human chromosomes while keeping their structure intact. The study, published in Science, represents a decisive breakthrough for synthetic and generative biology and for future advanced genetic therapies. The researchers developed a technology that makes it possible to move entire human chromosomes from one cell to another without damaging their DNA, to modify them in special “factory cells” made from mouse embryonic stem cells, and then to reintroduce them into final human cells. In these factory cells, the telomeres of human chromosomes – structures whose shortening is critical in aging processes and genomic stability – lengthen up to tenfold, then spontaneously return to typical human lengths once the chromosomes are transferred back into the recipient cells. It was also possible to eliminate the original chromosome from human cells and replace it with the engineered one, completing for the first time a full cycle of chromosome transplantation with unprecedented genomic fidelity. This approach allows scientists to address biological questions that have so far remained beyond the reach of traditional genome-editing tools (such as CRISPR-Cas). The new technology makes it possible to modify and causally analyze the human genome as an integrated system rather than gene by gene. It therefore becomes easier to evaluate the contribution of large regulatory regions, the role of so-called “dark DNA”, and the three-dimensional organization of DNA in the cell. Moreover, it offers a unique model for studying the chromosomal alterations typical of cancer, as well as the mechanisms underlying aging, including the dynamic behavior of telomeres. Looking ahead, this work paves the way for building synthetic chromosomes and genomes, designing cells with entirely new functions, generating cells and tissues with greater immunological compatibility and intrinsic resistance to viruses, and developing a new generation of gene therapies capable of addressing even complex and rare diseases. The experimental part of the research was conducted entirely in the United Kingdom thanks to the support of the Medical Research Council (MRC), the Wellcome Trust, and a Marie Skłodowska-Curie European Postdoctoral Fellowship awarded to Dr. Petris during his time abroad. The continuation and expansion of this line of research in Italy is now being carried out by Dr. Petris at the Fondazione Italiana Fegato and the University of Udine, thanks to competitive funding such as the My First AIRC Grant (AIRC) and the PNRR (Next Gen EU) – Young Researchers program. As Gianluca Petris emphasizes, “this is a result that only a few years ago would have been considered unattainable, and today it opens the door to a new generation of knowledge and technologies destined to have a major scientific, medical, economic, and social impact”.

The Interreg COHERENCE project – Cross Border Health Regulatory Alliance for Advanced Therapies – has launched a digital platform that supports researchers and clinicians in regulatory compliance for cell-based Advanced Therapy Medicinal Products. COHERENCE promotes a collaborative approach to research and development processes by capitalising on the experience gained by interregional partners in Italy and Slovenia. ICGEB, as the lead partner in the project, is pleased to announce the launch of a digital platform that supports researchers and clinicians in regulatory compliance for cell-based Advanced Therapy Medicinal Products (ATMPs). The web platform is available in three languages (Italian, Slovenian, and English). It offers a clear map of national (Italian and Slovenian) and European regulations, provides templates and checklists of the necessary forms for both countries (including the CTIS guide), and includes experimental protocols, publications, and conference information. Through a pilot action, the project aims to develop an open platform to guide researchers in regulatory compliance. It involves the design and conduct of a clinical trial to treat difficult wounds. In addition to advancing the development of an effective treatment for difficult wounds, the trial will test the platform, which will then be opened and expanded to encourage the participation of other research groups at the European level. The platform has been designed as an open, modular, and scalable tool to accelerate the transition from preclinical to clinical safely and ethically and to incorporate and integrate regulatory updates and new content.